Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
December 18, 2024 08:30 ET
|
Coherus BioSciences, Inc.
- Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer - REDWOOD CITY, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) --...
Coherus Management to Participate in the 2024 Citi Global Healthcare Conference
November 27, 2024 16:01 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in the 2024 Citi Global Healthcare...
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
November 06, 2024 16:01 ET
|
Coherus BioSciences, Inc.
– Net revenue of $70.8 million in Q3 2024 driven by 30% increase in UDENYCA® net revenue, quarter-over-quarter – – UDENYCA labeling and packaging production resuming at third-party contract...
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024 16:01 ET
|
Coherus BioSciences, Inc.
– Net revenue of $77.1 million in Q1 2024 – – CRI and ENB Therapeutics development partnership for toripalimab in ovarian cancer – – New debt and royalty financing replaces $75 million...
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
March 13, 2024 16:01 ET
|
Coherus BioSciences, Inc.
– Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 – – UDENYCA® net sales of $36.2 million in the fourth quarter and $127.1 million in FY 2023 – – CIMERLI® net...
Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium
January 18, 2024 16:05 ET
|
Coherus BioSciences, Inc.
– Data demonstrate early activity with casdozokitug/atezolizumab/bevacizumab; 38% objective response rate including three complete responses – – Data support casdozo as a promising novel...
Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress
December 06, 2023 04:00 ET
|
Coherus BioSciences, Inc.
– Casdozokitug has demonstrated anti-tumor activity alone and in combination with an anti-PD-1 antibody; two of nine squamous NSCLC patients had confirmed partial responses – – Data support...
Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)
November 03, 2023 08:30 ET
|
Coherus BioSciences, Inc.
– Data demonstrate distinct IL-27-mediated expression of genes associated with immune suppression in vitro, supporting ongoing clinical development of first-in-class anti-IL-27 antibody casdozokitug –...
Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
September 27, 2023 09:10 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced the presentation of three abstracts from its innovative immuno-oncology...